• New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

    March 22, 2017 A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer. Read more
  • Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

    March 20, 2017 Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients   Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in immuno-oncology. These blood-based tests, which were developed on Biodesix’s proprietary Diagnostic Cortex™ platform, may identify patients who derive significant benefit from anti-PD-1 monotherapy ... Read more
  • Biodesix® and Progenetics Announce Distribution Agreement for Israel

    March 9, 2017 March 9, 2017, Boulder, Colorado…Biodesix, Inc. (Boulder, CO, USA) and Progenetics LTD (Tel Aviv, Israel) announced today that they have entered into an international agreement where Progenetics will market and distribute kits for Biodesix’s GeneStrat® and VeriStrat® liquid biopsy tests for patients with non-small cell lung cancer (NSCLC). Both tests are now available for clinical use ... Read more
  • Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

    February 27, 2017 Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1 ddPCR Assay Measures mRNA Expressions from Immune and Cancer Cell; Key Step In Development of Immunotherapy Test New data from Biodesix® evaluating an assay in development demonstrated the potential to measure circulating PD-L1 through mRNA in blood through multiplexed droplet digital™ PCR (ddPCR, Bio-Rad, Inc.) detection. The assay uses proprietary ... Read more
  • Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

    February 15, 2017 Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1 ddPCR Test Measures mRNA Expressions from Immune and Cancer Cells   Poster Title: Development of ddPCR blood-based diagnostic tests that simultaneously measure mRNA expression from immune and cancer cells.   Poster Session Date/Time: February 24, 11:30AM – 1:00PM; 5:30PM-6:30PM   Presenting Author: Hestia Mellert, Ph.D Corresponding Author: Gary Pestano, Ph.D   Location: Regency Ballroom, Hyatt ... Read more
  • Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

    February 2, 2017 Actionable mutation results from a single blood draw, 72 hour turnaround time   February 2, 2017, Boulder, CO….Biodesix®, Inc. announced today that the GeneStrat® test, a liquid biopsy for patients with cancer, now includes ROS1 and RET in addition to EGFR sensitizing; EGFR resistance (T790M), KRAS, BRAF mutations; and EML4-ALK fusions. GeneStrat is a non-invasive, blood test ... Read more
  • Clin-TOF Successfully Integrated into VeriStrat® Workflow

    January 26, 2017 Study Results, Presented at MSACL, Advance Biodesix®/Bioyong Agreement Study results presented today demonstrate the feasibility of running the VeriStrat® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and deploying a version of the VeriStrat® test in Greater China. The data were presented in a poster at the ninth annual conference of the Association for ... Read more
  • Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

    January 9, 2017 US $38M; Potential Expansion into Other Asia/Pacific Countries, Additional Liquid Biopsy Products Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test, a precision medicine diagnostic for patients with non-small ... Read more
  • Biodesix® Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

    December 13, 2016 VeriStrat® Test Shown To Have Clinical Utility in Predicting Overall Survival of Afatinib-Treated Patients With Lung Cancer   December 13, 2016, Boulder, Colorado… Two studies demonstrating the clinical utility of the VeriStrat® test in the management of patients with non-small cell lung cancer (NSCLC) were presented last week at the 17th World Conference on Lung Cancer, hosted ... Read more
  • Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

    December 7, 2016 Biodesix won the award for “Innovative Company of the Year” last night at the 2016 IQ Awards and Innovation Summit presented by BizWest Media. The other finalists in the category were Fort Collins-based Madwire and n.io of Broomfield. “We are really in the business of helping cancer patients to determine the most effective treatment for their ... Read more